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The current standard of care to treat acute stroke patients presenting within 4.5 hours of stroke symptom onset is
intravenous (IV) Alteplase.1 Over the past decade, tremendous efforts have been made to challenge the conventional
window of 4.5 hours for the administration of Alteplase to expand the patient population which can benefit from
thrombolysis. Based on the recent meta-analysis, 2 we have strong evidence supporting the use of IV thrombolysis in
patients presenting between 4.5 to 9 hours of symptom onset with favorable perfusion imaging and it appears that the
era of the conventional 4.5 hours window may be coming to an end"
In this editorial, we would like to highlight a few points from recently published IV thrombolysis extended window trials;
EXTEND3, ECASS4-EXTEND4, and EPITHET5. These trials compared the outcomes in patients presenting in an extended
window period between 4.5 to 9 hours of symptom onset and receiving either IV Alteplase or placebo.
Until the WAKE-UP 6 trial published in 2018, stroke on awakening was one of the exclusion criteria for thrombolytic
therapy due to unknown time of symptom onset. The WAKE-UP trial was the first to assess patients with unknown time
of symptom onset on the basis of diffusion-weighted image (DWI) and fluid attenuated inversion recovery (FLAIR)
mismatch pattern. It showed that patients with DWI-positive and FLAIR-negative pattern fall within the 4.5 hour window
of stroke onset and would benefit from thrombolysis. Thomalla G et al.7 showed that this selection approach for
wake-up strokes identifies only about 62% of the patients in the 0–4.5 hour time window. Therefore, this approach
excludes wake-up stroke patients presenting beyond 4.5 hours who might have favorable perfusion imaging and can
benefit from thrombolysis.
The aforementioned extended window trials included wake-up stroke patients in staggering numbers, constituting as
high as 65% and 69% of the patients included in EXTEND 3 and ECASS4-EXTEND4 respectively, and totaling
approximately half of all patients included according to a recent meta-analysis of the individual patient data from the
extended window trials.2 It is interesting to note that these trials unanimously defined the time of stroke onset for
wake-up stroke as the midpoint between sleep-onset and time of awakening. To the best of our knowledge, no
rationale or reference for this definition was provided in either of the studies.
Studies have shown that wake-up stroke patients often have a likelihood of having had an onset within a few hours of
awakening and are known to show similar early ischemic changes on imaging if seen within 3 hours of symptom
recognition as compared to patients with known time of symptom onset.8 Furthermore, studies also show that there
is an increased likelihood of stroke occurrence between 6 am and 12 noon.9 This scientific data questions the
inclusion of wake-up stroke in the extended window trials and points to the fact that out of the 51% patients included
in these trials under the umbrella of wake-up stroke2, at least 62% would fall under the 4.5 hour window due to the
chance that stroke onset was within a short duration before awakening.7
Inclusion of wake-up strokes (time of stroke onset defined as the midpoint between sleep-onset and time of
awakening) in the aforementioned extended window trials raises debatable effect on the outcomes. Further clinical
studies are required to solidify the evidence of improved outcomes of IV thrombolysis in the extended window by
selecting patients truly in an extended window with known time of symptom onset. On the other hand, there is also a
need to have more definitive imaging markers to categorize wake-up strokes with respect to time of symptom onset.
DWI-FLAIR mismatch pattern can be used to classify wake-up stroke patients as under 4.5 hours and beyond 4.5
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hours.
Secondly, the IV thrombolysis extended window trials were conducted over a lengthy span of time between the years
2001 and 2018.3,4,5 Over this time period the landscape of management of large vessel occlusion (LVO) has drastically
changed and good outcomes with thrombectomy have been reported at 6, 16, and 24 hours after time last known
well.10 In the IV thrombolysis extended window trials, 61% of the patients had LVO.2 As rightly identified by the
investigators of the meta-analysis,2 these patients will now be eligible for thrombectomy as per the recent guidelines.1
The recently published clinical trials, in light of the evolving landscape, actually raised more question than answers. The
possible treatment options for LVOs could be either only IV thrombolysis, or only thrombectomy, or both thrombolysis
and thrombectomy simultaneously. We would like to ask a few questions here. Is there a benefit of IV thrombolysis
when the patient is eligible for thrombectomy? Can IV thrombolysis produce the same reperfusion and functional
outcomes as mechanical revascularization? However, it is true that there is a benefit of IV thrombolysis for LVOs in
lower/middle-income countries where thrombectomy facilities are not readily available.
Lastly, the extended window trials bring to light the question, which imaging modality is more appropriate or superior
to assess perfusion changes while determining the eligibility for acute intervention with IV thrombolysis. There was an
almost even split between two imaging modalities, as 47% and 53% of the patients were imaged with CT perfusion
and perfusion-diffusion MRI respectively in the extended window trials.2 We think it will be of importance to analyze the
data from these trials and differentiate between the outcomes on the basis of these imaging modalities.
In conclusion, during the last few years acute stroke management has evolved significantly as a result of multiple
recently published positive clinical trials. As of 2013 in the United States, only 6.5% of patients received intravenous
thrombolysis for ischemic stroke.11 Extending the time window will definitely increase the intravenous thrombolysis
utilization which will ultimately result in a greater percentage of patients returning to normal or near-normal function.
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